Phase 1 Parkinson's Disease Trial, Recruiting NCT07371338 Sponsor: Innopeutics Corporation Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 1 Parkinson's Disease Trial, Recruiting

NCT07371338
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Parkinson's disease using a specific set of recognised diagnostic standards (known as the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria).
  • People aged between 50 and 80 years old (inclusive) at the time of signing the consent form, with a confirmed diagnosis of Parkinson's disease.
  • People who have been living with Parkinson's disease for at least 10 years before the screening visit, based on their medical history or records.
  • People whose Parkinson's disease symptoms are not adequately managed, even after trying all available standard treatments — either alone or in combination — as assessed by the trial doctor.
  • People whose Parkinson's disease is rated at stage 4 or 5 on the Hoehn & Yahr scale during an "off" period (meaning when medication is not providing benefit) at the screening visit (confirm with trial site if unsure what this means for your situation).

Who may not be able to join:

  • People who have been diagnosed with Parkinson's disease dementia, as determined by the trial doctor using criteria set by the Movement Disorder Society Task Force.
  • People who score 24 or below on a specific memory and thinking assessment called the Korean Mini-Mental State Examination at the screening visit.
  • People whose brain scan results (PET and MRI) show signs suggesting a condition related to, but different from, standard Parkinson's disease, as assessed by the trial doctor or an imaging specialist.
  • People who experience significant visual hallucinations, even if they do not meet the full criteria for Parkinson's disease dementia, as judged by the trial doctor.
  • People whose Parkinson's-like symptoms were caused by medication, as confirmed by their medical history or records and determined by the trial doctor.
  • People whom the trial doctor considers unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82-2-3499-4266

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Innopeutics Corporation
Registry
ClinicalTrials.gov
Start date
30 May 2026
Est. completion
31 October 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Safety Evaluation: dose-limiting toxicity (DLT); Safety Evaluation: Severity and frequency of reported adverse events; Safety Evaluation: clinically-relevant changes in laboratory testing assessed by medical personnel; Safety Evaluation: clinically-relevant changes in physical exams assessed by medical personnel

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov